ESFANDIAR MAFI: Open Payments
NPI 1780656447 · AMHERST, NY. Company-reported industry payments from CMS Open Payments. A payment does not imply wrongdoing.
See the full provider profile for registry, prescribing and billing details.
Industry payments (Sunshine Act)
Source: CMS Open Payments general payments. Payments from drug and device companies are reported by the companies; they do not imply wrongdoing and are separate from Medicare billing.
$870 in 43 payments from 16 companies in 2025. Trend: 2023 $384 · 2024 $988 · 2025 $870
Food & beverage: $870
| Company | Payments | Amount |
|---|---|---|
| Takeda Pharmaceuticals U.S.A., Inc. | 7 | $139 |
| Exact Sciences Corporation | 7 | $115 |
| Regeneron Healthcare Solutions, Inc. | 4 | $100 |
| Abbott Laboratories | 3 | $69 |
| PFIZER INC. | 3 | $66 |
| Madrigal Pharmaceuticals | 2 | $64 |
| Novo Nordisk Inc | 3 | $54 |
| Corcept Therapeutics | 3 | $50 |
| MOTIVA USA, LLC | 1 | $36 |
| Salix Pharmaceuticals, a division of Bausch Health US, LLC | 2 | $34 |
Products named: ENTYVIO, DUPIXENT, The Cologuard Plus Collection Kit, FREESTYLE LIBRE 3, REZDIFFRA, Korlym, Ozempic, Motiva Implant Matrix.
Industry payments across NY — which companies pay providers there.
